HIV Testing 101 – Part 2 of 2
[Note: Part 1 of this article appeared in AIDS Treatment News #374, November 23, 2001.]
Detecting Acute HIV Infection
Shortly after getting infected with HIV, many patients have an acute (or “primary”) HIV infection, a period of flu-like illness with symptoms like fever and malaise that could be caused by influenza or many other diseases. Many scientists and physicians believe it is important to treat during acute this HIV infection (provided, of course, that it gets diagnosed then). But there are still questions remaining about treating acute infection. (1,2)
To confirm an acute HIV infection in symptomatic individuals with potential HIV risk factors, current guidelines (2) recommend use of HIV RNA (viral load) tests. [The regular HIV antibody test will not detect acute HIV infection because the patient is still in the “window period” before antibodies have been produced.] False positives can occur with viral load tests, but a review of the data in the August, 1999 American Family Physician (1) suggests it is usually possible to differentiate these from the real thing: “During the symptomatic phase of acute HIV infection, the viral RNA shows in excess of 50,000 copies per mL. Three instances of false-positive HIV-1 RNA tests have been reported; in each instance, however, the person was not having symptoms and the viral load [reported] was less than 2,000 copies per ml. The presence of high-titer HIV-1 RNA (more than 50,000 copies per mL) in the absence of HIV antibodies establishes diagnosis of acute HIV infection.”
At present there is no viral load test approved by the FDA for the purpose of diagnosing HIV infection in individual patients. In September the FDA did approve a viral load test developed by National Genetics Institute for screening large pools of donated blood plasma.
If viral load testing is not available, current treatment guidelines (2) recommend testing for p24 antigen, a viral protein. In either case, the diagnosis should be confirmed by antibody testing once the window period has elapsed.
A variation of standard antibody testing, presently approved in the U.S. only for research, is the sensitive/less sensitive or “detuned” ELISA. The detuned test takes advantage of the fact that antibody levels rise in a predictable pattern during roughly the first four to six months after infection, eventually reaching a plateau that often stays roughly constant for many years.
Current ELISAs can detect relatively low levels of antibodies. The detuned testing approach involves taking samples that are confirmed HIV-positive by these tests, but then retesting them with a less sensitive, diluted ELISA. This less sensitive test can only detect antibodies at the higher levels achieved during the period six months or more after infection. Thus, the detuned approach distinguishes between recent and established infections, so it is a potentially valuable tool for epidemiologists trying to chart the pattern of new infections. It is not used in patient care at this time.
Accuracy of Antibody Testing — and Denialist Arguments
Constantine (3) sums up the general consensus among experts and institutions such as the CDC when he says “The antibody tests are nearly 100 percent sensitive (unless a person is in the window period) and about 99 percent specific.” Such levels of accuracy have been documented in a number of studies, including periodic evaluations of commercially available test kits conducted by the World Health Organization.
Still, AIDS denialists (the self-styled “AIDS dissidents” who claim that HIV is either harmless or doesn’t exist) continue to claim that HIV antibody tests are unreliable. Many of their arguments seem to derive from a series of articles written by Christine Johnson in the mid-1990s, several of which are available on denialist web sites. (4,5,6)
Johnson’s argument boils down to two key points: 1) HIV has never been properly isolated, so the HIV proteins used in the tests haven’t been proven to actually come from HIV, 2) Even if HIV is real, the proteins are not unique and cross-react with many other antigens, rendering a positive result meaningless. Johnson’s list of some 60 factors she describes as “known to cause false-positive HIV-antibody test results” turns up regularly in denialist literature.
The claim that HIV has never been properly isolated, based on the writing of a group in Perth, Australia, is too technical and complex to examine thoroughly here. However, it is elegantly demolished in Michael Coon’s article, “HIV, AIDS and the Distortion of Science,” available on the AEGIS web site. (7) In short, Coon argues that the Perth Group set up artificial, phony criteria for “proof’ of HIV’s isolation that bear no relation to how virology works in the real world.
The second argument, though, contains a grain of truth. Cross-reactions are possible, and a number of factors can, on occasion, produce false-positive HIV antibody test results. What Johnson fails to address in any detail is that such effects are typically transient and rare, affecting few individuals.
For example, one well-known causes of falsepositives Johnson lists is influenza vaccination. (8,9) But she neglects to mention that a key reference she cites described the phenomenon as “infrequent” and “of short duration,” while in another only 10 false-positives were found among 133,000 individuals who had flu shots prior to testing, with half of those reverting to negative within six months. (9)
Constantine adds, “I doubt very much that it has been firmly documented that 60 factors can interfere with antibody tests. In fact, it has been long sought to try and identify the causes of false positive results, and only a few have really been documented to consistently interfere (e.g. pregnancy, certain autoimmune diseases, some infectious diseases). However, even these do not consistently cause problems with the tests… There are very few false positives that can’t be resolved with further testing.”
Consent, Anonymity, and Counseling
(1) Anonymous Testing
Prior to HIV, blood testing was considered a routine procedure, with such minimal dangers that formal informed consent was rarely required. But because HIV presented massive psychosocial risks, from employment discrimination to rejection by family and reduced access to health care, special procedures were widely adopted.  These included specific informed consent and pre- and post-test counseling. Many states set up test sites where people could get tested anonymously, without ever giving their name.
Anonymous testing (other than the home test, below) was never universally available, Morin notes, but was and is offered in many places, despite the recent move by numerous states to adopt a system of names-based HIV reporting (a few, including California, are implementing HIV reporting via codes that don’t reveal the person’s name). The CDC and others urged that the option for anonymous testing should be kept available, believing fear of disclosure would keep some from being tested, and most states have followed this recommendation.
Because local laws and procedures vary, Morn recommends that anyone concerned about anonymity or disclosure contact their local health department to check. A number of AIDS service organizations operate hotlines, which should also be able to provide this information.
Those living in areas with no anonymous test sites can still be tested anonymously via home collection test kits, which are sold in many drug stores. Introduced in the mid-’90s, the kits were controversial because counseling is provided by telephone rather than in person. Morn says fears that telephone counseling would prove inadequate haven’t been borne out, but sales of the kits have been less than expected. Still, “the FDA ruled that you cannot bar their sale in any state, so even in states that don’t have anonymous testing people can use home test kits to anonymously be tested,” he says.
But, he adds, things change when the individual seeks treatment: “If you go to your doctor and the doctor does a viral load test, you get reported through the viral load test to the health department. So there’s no way to keep treatment for HIV anonymous.”
(2) Consent and Counseling
As with anonymity, requirements for consent and counseling vary from state to state. Most, but not all, states require specific informed consent — sometimes in writing — for HIV testing. Approximately one-fifth of states require pre-test counseling, with many listing specifically what that counseling must include. The U.S. Department of Health and Human Services recommends that all HIV testing include counseling that covers the test itself, basic information about HIV and AIDS, how to avoid spreading the virus, the confidentiality of the results, the possible impact of the results on the person being tested, and discussion of to whom results should be disclosed, such as sex or needle-sharing partners.  Counselors should also be able to give referrals to medical and psychosocial support services.
Counseling and consent procedures vary greatly, remain controversial and may continue to change. Even states that require informed consent may allow HIV testing without consent in special circumstances. For example, many permit involuntary testing of a patient when health workers have been exposed to the person’s blood. Some test prisoners or people accused of sex crimes, and at least two, New York and Connecticut, require mandatory testing of newborns, which indirectly reveals the mother’s HIV status, but does not tell if the infant has been infected.
In October 2000 the Institute of Medicine recommended that HIV testing be included as a routine part of prenatal care. Women would be informed of the test and could opt out, but specific consent would not be required. Thus far the U.S. Public Health Service has stopped short of urging an end to informed consent in such cases, simply suggesting that providers recommend HIV testing to all pregnant patients.
(1.) Perimutter, Barbara Lee et al, “How to Recognize and Treat Acute HIV Syndrome,” American Family Physician, August, 1999, www.aafp.org/afp/990800ap/535.html.
(2.) U.S. Public Health Service, “Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents” (August 13, 2001), http://www.hivatis.org/trtgdlns.html.
(3.) Constantine, Niel, “HIV Antibody Assays,” HIV Knowledge Base, HIV InSite Sept. 2001, http://hivinsite.ucsf.edu/InSite.jsp?page=kb-02-02-01.
(4.) Johnson, Christine, “Whose Antibodies Are They Anyway?” Continuum, Sept./Oct., 1996, http://www.virusmyth.net/aids/data/cjtestfp.htm.
(5.) Johnson, Christine, “Is Anybody Really Positive?” HEAL Magazine, 1995, http://www.virusmyth.net/aids/data/chjtests2.htm
(6.) Johnson, Christine, “Playing Russian Roulette in the Laboratory,” Virusmyth, http://www.virusmyth.net/aids/data/chjroulette.htm.
(7.) Coon, Michael, “HIV, AIDS and the Distortion of Science,” Misc Health AIDS, August, 2000, http://www.aegis.org/topics/hiv_exist.html.
(8.) MacKenzie, William, et al, “Multiple False-positive Serologic Tests for HIV, HTLV-l and Hepatitis C Following Influenza vaccination, 1991,” Journal of the American Medical Association, vol. 268, No. 8, Aug. 26, 1992, p. 1015-1017.
(9.) Arnold, NL, and others. “Donor Follow-up of Influenza vaccine-Related Multiple viral Enzyme Immunoassay Reactivity,” Vox Sang, vol. 67, No. 2, 1994, p. 191-194.
(10.) Wolf, Leslie, and Lo, Bernard, “Ethical Dimensions of HIV/AIDS,” AIDS Knowledge Base, HIV InSite, http://hivinsite.ucsf.edu/InSite.jsp?page=kb-08-01-05.
(11.) U.S. Department of Health and Human Services, “Voluntary HIV Counseling and Testing: Facts, Issues and Answers,” http://hivinsite.ucsf.edu/InSite.jsp? doc=2098.2099&page=pr-04-03.
(12.) Food and Drug Administration, “HIV and AIDS,” http://www.fda.gov/oashi/aids/test.html (this regularly-updated page contains information about FDA actions relating to HIV-related tests).
COPYRIGHT 2001 John S. James
COPYRIGHT 2002 Gale Group